Centre for Tumour Biology, Barts Cancer Institute - a CRUK Centre of Excellence, Queen Mary University of London, London, UK.
Centre for Tumour Biology, Barts Cancer Institute - a CRUK Centre of Excellence, Queen Mary University of London, London, UK; Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, London, UK.
J Hepatocell Carcinoma. 2014 May 29;1:43-54. doi: 10.2147/JHC.S48958. eCollection 2014.
Hepatocellular cancer (HCC) is currently the third leading cause of cancer death worldwide. The prognosis of patients diagnosed with late-stage disease is dismal due to high resistance to conventional systemic therapies. The introduction of sorafenib, despite its limited efficacy, as the standard systemic therapy for advanced HCC has paved a way for targeted molecular therapies for HCC. Fibroblast growth factor (FGF) signaling plays an important role in the developing embryo and the adult. The FGF signaling pathway is often hijacked by cancer cells, including HCC. Several alterations in FGF signaling correlate with poor outcome in HCC patients, suggesting that this family of signaling molecules plays an important role in the development of HCC. Multikinase inhibitors targeting FGF signaling are currently under investigation in clinical trials. This review discusses the current understanding of the biological and clinical implications of aberrant FGF signaling in the prognosis, diagnosis, and treatment of HCC.
肝细胞癌 (HCC) 是目前全球癌症死亡的第三大主要原因。由于对传统系统治疗的高度耐药性，晚期疾病患者的预后较差。索拉非尼的引入，尽管疗效有限，但作为晚期 HCC 的标准系统治疗方法，为 HCC 的靶向分子治疗铺平了道路。成纤维细胞生长因子 (FGF) 信号在胚胎发育和成人中起着重要作用。FGF 信号通路经常被包括 HCC 在内的癌细胞劫持。FGF 信号通路的几种改变与 HCC 患者的不良预后相关，表明这一家族的信号分子在 HCC 的发展中起着重要作用。目前正在临床试验中研究针对 FGF 信号的多激酶抑制剂。这篇综述讨论了异常 FGF 信号在 HCC 的预后、诊断和治疗中的生物学和临床意义的最新认识。
